What is MicroSure?
Founded in 2016 and headquartered in Eindhoven, Netherlands, MicroSure is a medical technology firm dedicated to enhancing patient outcomes through advanced robotic systems. The company's flagship innovation, MUSA, represents the world's first surgical robot specifically engineered for open microsurgery. By providing superhuman precision, MUSA enables surgeons to perform complex interventions that were previously considered impossible due to human physiological limitations. The company operates at the intersection of high-end engineering and clinical practice, maintaining close collaborative ties with microsurgeons to ensure that its technological advancements directly address the most pressing needs in the operating room. As a key player in the medical robotics sector, MicroSure is effectively bridging the gap between traditional surgical techniques and the future of automated, high-precision medical care.
How much funding has MicroSure raised?
MicroSure has raised a total of $46.1M across 3 funding rounds:
Series A
$3M
Series B
$3.2M
Other Financing Round
$39.9M
Series A (2018): $3M with participation from Innovation industries
Series B (2021): $3.2M led by Invest-NL, Innovation Industries, Ten Cate Investeringsmaatschappij, and BOM Brabant Ventures
Other Financing Round (2023): $39.9M, investors not publicly disclosed
Key Investors in MicroSure
Invest-NL
Invest-NL is the national financing and development institution dedicated to fostering a sustainable and innovative Netherlands, focusing on sectors such as Life Sciences and Deep Tech.
Innovation Industries
Innovation Industries is a specialized investment firm that supports high-growth technology companies, providing the necessary capital and expertise to scale complex engineering solutions.
BOM Brabant Ventures
BOM Brabant Ventures is the investment arm of the Brabant Development Agency, focusing on early-stage and growth-stage companies that drive regional economic innovation.
What's next for MicroSure?
With the successful closure of this major strategic investment, MicroSure is poised to transition into a phase of rapid commercial expansion and technological refinement. The company is expected to prioritize the scaling of its manufacturing capabilities to meet the growing demand for the MUSA platform across international markets. Furthermore, the influx of capital will likely support ongoing research and development initiatives aimed at expanding the clinical applications of its robotic systems. As MicroSure continues to navigate the complex regulatory and clinical environments of the medical device industry, the focus will remain on securing broader hospital adoption and establishing long-term partnerships with leading surgical centers. This strategic roadmap is designed to solidify MicroSure's market position as the standard-bearer for robotic-assisted microsurgery, ultimately driving long-term value for stakeholders and improving the standard of care for patients worldwide.
See full MicroSure company page
